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not able to form new tumors and have high expression of 
CD127 on their T cells, a marker for immunological memory. 
This new treatment will be further investigated in a Phase I 
study for patients with an oligometastatic solid tumor 
(NCT02086721). 
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Purpose or Objective: The novel combretastatin analogue, 
OXi4503, is a vascular disrupting agent (VDA) that has 
recently been shown to significantly enhance a stereotactic 
radiation treatment. This was achieved using an OXi4503 dose 
of 10 mg/kg combined with a stereotactic treatment of 3 x 
15 Gy. The current study was undertaken to determine the 
OXi4503 dose dependency when using different stereotactic 
radiation dose schedules. 
 
Material and Methods: A C3H mammary carcinoma grown in 
the right rear foot of female CDF1 mice was used in all 
experiments. Treatments were performed in restrained non-
anaesthetised animals when tumours had reached 200 cubic 
mm in size. Tumours were locally irradiated (230 kV x-rays) 
with 3 fractions of radiation varying from 5-20 Gy (each 
fraction given with an interval of 2-3 days over a one week 
period). OXi4503 was dissolved in saline prior to each 
experiment; once prepared it was kept cold and protected 
from light. Various doses (5-25 mg/kg) were intraperitoneally 
injected into mice 1-hour after each irradiation treatment. 
Three days after the final irradiation the tumours were 
subjected to a clamped top-up dose which involved giving 
graded radiation doses with the tumour bearing leg clamped 
for 5 minutes before and during irradiation. The percentage 
of mice in each treatment group showing local tumour 
control 90 days after irradiating was then recorded. Following 
logit analysis of the clamped top-up radiation dose response 
curves, the TCD50 values (radiation dose to control 50% of 
tumours) were estimated. A Chi-squared test (p<0.05) was 
used to determine significant differences between the TCD50 
values. 
 
Results: The clamped top-up TCD50 values (with 95% 
confidence intervals) obtained following irradiation with 3 
treatments of 10, 15 or 20 Gy were found to be 42 Gy (38-
47), 30 Gy (23-39), and 0.8 Gy (0.3-2.3), respectively. A plot 
of the TCD50 values against the stereotactic doses gave rise 
to a linear response (slope = -4.1; correlation coefficient = 
0.97). OXi4503 significantly decreased the clamped radiation 
top-up TDC50 values and this affect appeared to be 
independent of both the ambient radiation dose applied with 
each of the 3 fractions and the VDA dose; the curve showing 
the TCD50 values against stereotactic radiation dose was 
similar to that for radiation alone (slope = -4.3; correlation 
coefficient = 0.94), but the radiation + OXi4503 curve was 
some 15 Gy lower than the radiation only curve. 
 
Conclusion: OXi4503 is an effective agent for enhancing a 
stereotactic radiation treatment. But, the enhanced response 
appeared to be a simple additive effect independent of both 
the radiation dose applied with each fraction and the VDA 
dose used. 
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Purpose or Objective: Hypoxia is a common feature of solid 
tumors. Conventional treatments such as chemo- and 
radiotherapy (RT) are less effective against hypoxic tumor 
cells. Hypoxia-activated prodrugs (HAPs) are specifically 
activated in hypoxia to target hypoxic cells as well as 
adjacent oxygenated tumor cells via their bystander effect. 
DTP-006 is a newly synthesized nitroaromatic HAP with highly 
favorable properties: 1) activation under hypoxia, 2) high 
bystander effect, 3) excellent aqueous solubility, 4) murine 
oral bioavailability and 5) no off-mechanism activation by 
human aerobic reductases NQO1 and AKR1C3. Here we show 
the effects of DTP-006 on tumor cell viability, spheroid 
growth and radiation resistant tumor cells in vivo, and assess 
its pharmacokinetics and oral bioavailability in mice. 
 
Material and Methods: The one-electron reduction potential 
(E1) of DTP-006 was determined by pulse and steady state 
radiolysis. IC50 viability ratios were assessed in 2D cell 
culture exposed to normoxic or anoxic (≤0.0 2% O2) 
conditions. H460 multicellular layers (MCLs) under aerobic 
(5% CO2, 95% O2) or anoxic (5% CO2, 95% N2) conditions were 
incubated with DTP-006 for 5 h after which cells were plated 
for clonogenic survival. H460 spheroids were incubated with 
DTP-006 upon confirmation of a hypoxic core. NIH-III mice 
bearing H460 tumors received a single i.p. dose of DTP-006 
(781 mg/kg) after irradiation (10 Gy) of tumors. 18 h later 
tumors were excised and single cell suspensions were 
generated and plated for clonogenic survival. Tumor-free 
female NIH-III mice received a single i.v. or oral dose of DTP-
006 (383 mg/kg). Terminal blood samples collected at time 
points via cardiocentesis were analyzed by LC/MS/MS. Plasma 
half-life (T1/2) and absolute oral bioavailability (Fabs) were 
calculated. 
 
Results: DTP-006 has an E1 value of -351 mV, indicating 
strong oxygen inhibition of nitro radical formation. IC50 were 
lower in anoxia than normoxia by factors of 203 (MDA-MB-
468), 55 (C33A), and 20 (HCT116). In a H460 MCL clonogenic 
assay, 100 µM DTP-006 caused 99% cell kill under anoxia but 
exhibited no aerobic cell kill. It caused a concentration-
dependent growth delay in spheroids, where 250 µM 
completely halted growth. A single dose of DTP-006 caused a 
significant loss of clonogenicity when combined with RT in an 
in vivo excision assay (log cell kill 2.35 relative to control). 
T1/2 after oral administration was 0.82 h and bioavailability 
was 47%. 
 
Conclusion: DTP-006 kills tumor cells only in severe hypoxic 
conditions in vitro, reduces growth of tumor cell spheroids, 
and sterilizes radiation resistant tumor cells in vivo. It has 
clinically relevant bioavailability after oral administration. As 
such, DTP-006 is a promising new HAP with potentially 
favorable properties for clinical use. Further studies to 
determine the antitumor effects of DTP-006 as a 
monotherapy and in combination with RT in several 
preclinical tumor models are ongoing. 
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Purpose or Objective: Glioblastoma multiforme (GBM) is the 
most common malignant brain tumour in adults. The current 
standard of care includes surgery followed by radiotherapy 
(RT) and chemotherapy with temozolomide (TMZ). Treatment 
often fails due to the radiation and TMZ resistance of a small 
percentage of cells with stem cell-like behavior (CSC). The 
Notch signaling pathway is expressed and active in human 
glioblastoma and Notch inhibitors attenuate tumor growth in 
vivo in xenograft models. Here, we investigate the efficacy of 
a clinically (FDA) approved γ-secretase inhibitor (GSI) 
RO4929097 in tumor control in combination with standard 
care of treatment (TMZ+RT) in an orthotopic glioma tumour 
model.  
 
Material and Methods: Treatment efficacy in vitro was 
tested in 2D cultures using proliferation and clonogenic 
survival assays. 3D sphere assays were used as a model for 
pharmacological treatment response with quantification of 
spheroid growth delay in the different different treatment 
arms. Flow cytometry was used to detect cells expressing 
stem cell markers. Luciferase-expressing U87 cells were 
intracranially injected into the brain of CD-1 mice. Tumor 
volume was quantified using contrast-enhanced microCT and 
bioluminescence imaging. Animals received TMZ (ip), 
RO4929097 (GSI, orally) or radiation (RT, 8Gy) alone or in 
combination. RT dose was calculated and prescribed using 
SmART-Plan software with two 5-mm parallel-opposed beams 
placed at the center of the tumour. 
 
Results: GSI in combination with RT and TMZ attenuated 
tumour cell proliferation, clonogenic survival as well as 
glioma spheroid growth. The expression of glioma stem cell 
markers SOX2 and CD133 was blocked by single or combined 
treatments with Notch inhibitors in vitro. Using our image 
guided micro-CT and radiotherapy platform in vivo, a 
significant growth delay was observed in GSI-, RT- and TMZ-
only treated groups compared to the control group. Standard 
of care treatment (RT + TMZ) or addition of GSI to either TMZ 
or RT irradiation resulted in a significant growth delay and 
prolonged survival. Strikingly, the longest tumour growth 
delay together with an increase in median survival was 
observed in mice treated with the triple combination 
(GSI+RT+TMZ), with 1 out of 4 mice showing tumour cure. 
 
Conclusion: We show in an orthotopic glioblastoma mouse 
model that adding a clinically approved Notch inhibitor to the 
TMZ/RT standard of care results in a significant growth delay 
and increased overall survival. The observed therapeutic 
benefit is promising for clinical translation in order to 
increase survival in patients bearing glioblastoma with active 
Notch signaling. 
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Purpose or Objective: It is well known that PI3K/Akt 
pathway is hyperactivated in K-RAS mutated tumor cells and 
is involved in radioresistance. Exposure to ionizing radiation 
induces activation of DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs) as an essential enzyme for repair of DNA 
double-strand breaks (DSBs) through non-homologous end 
joining. Radiation-induced DNA-PKcs activity is partially 
dependent on serine/threonine kinase Akt1. In this study, 
role of DNA-PKcs in Akt1-mediated DSBs repair and post-
irradiation cell survival was investigated. Likewise, a direct 
physical interaction of Akt1 with DNA-PKcs was studied. 
 
Material and Methods: Non-small cell lung cancer cell line 
A549 and colorectal cancer cell line HCT116 with point 
mutations in K-RAS gene were utilized. Complex formation of 
Akt1 with DNA-PKcs and role of Akt1 in DSBs repair were 
tested by immunoprecipitation and γH2AX foci assays, 
respectively. Localization of Akt1 to DSB site was tested by 
immunofluorescence staining and confocal microscopy of P-
Akt (S473) and γH2AX following microbeam laser irradiation 
and after exposure to ionizing radiation. To determine the 
potential interacting domain of Akt1 with DNA-PKcs; GST, 
GST-Akt1 full-length, GST-Akt1-N-terminal fragment (1–150 
a.a.), and GST-Akt1-C-terminal (151–480 a.a.) proteins were 
incubated with purified DNA-PKcs and pull-down assay was 
performed. In order to identify the domain of DNA-PKcs that 
interacts with Akt1, constructs expressing four distinct 
fragments of DNA-PKcs (1-426, 427-1400, 2401-3850, 3700-
4128 a.a) tagged with EGFP and full length Akt1 tagged with 
mCherry were produced. Akt1/DNA-PKcs was studied in A549 
cells, transiently transfected with the appropriate constructs. 
 
Results: Akt1 formed a complex formation with DNA-PKcs in 
the nuclear fraction immediately after irradiation. Nuclear 
Akt1 was co-localized with γH2AX foci and found to be 
essential for the efficient repair of ionizing radiation-induced 
DSBs and post-irradiation cell survival, in a DNA-PKcs 
dependent manner. A direct physical interaction of DNA-PKcs 
to the C-terminal domain of Akt1 could be demonstrated. 
Additionally, Akt1 was found to make physical interaction not 
only with the C-terminal domain of DNA-PKcs (3700-4188 
a.a.) but also with the N-terminal domain (1-426 a.a.). 
 
Conclusion: Akt1, through a direct physical interaction with 
DNA-PKcs, regulates repair of ionizing radiation-induced 
DSBs. Thus, due to overexpression of Akt1 in tumor cells and 
constitutive Akt activity in K-RAS mutated tumors cells, Akt1 
can be proposed as a tumor specific target for 
radiosensitization. 
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Purpose or Objective: Total mesorectal excision is the 
cornerstone of rectal cancer treatment and preoperative 
(chemo)radiotherapy and adjuvant chemotherapy are often 
administered. This population-based study compares the 
survival in clinical stage I-III rectal cancer patients who 
received either preoperative radiotherapy, preoperative 
chemoradiotherapy or no preoperative therapy. The effect of 
type of radical resection and adjuvant chemotherapy on 
survival was also investigated. 
 
Material and Methods: Patients diagnosed between January 
2006 and December 2011 with clinical stage I-III rectal 
adenocarcinoma were retrieved from the national Cancer 
Registry database. Only first primary invasive rectal tumors 
were included and only patients who underwent a radical 
resection were retained. The observed survival was 
